JAX Clinical Knowledgebase (JAX-CKB)

JAX-CKB: #PrecisionMedicine platform by @jacksonlab for interpreting human #cancer variants, #genomics & #proteomics, to match to therapies and #clinicaltrials.

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

CKB's New #cancer variant navigation is out! Learn more here: https://t.co/zZZv1nQaoR

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Interesting study on how IL-17 can drive resistance to anti-PD-L1 treatment! #immunotherapy #cancerresearch #cytokines

[Journal of Experimental Medicine @JExpMed]

Xing Chen et al. report that IL-17, a proinflammatory cytokine widely associated with poor prognosis in solid tumors, drives the therapeutic failure of anti–PD-L1. https://t.co/F2ylfKTW9m

From our #Cancer #Immunotherapy collection: https://t.co/vZLDRiauiJ

#SITC22

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

#AMPath22 attendees, looking for a resource to interpret genomic variants and find treatment options and clinical trials? Come visit us at booth #940 and ask for a CKB demo! #ClinicalKnowledgebase #PrecisionMedicine #PathTwitter 🧬

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Check out our latest blog post on how you can use CKB as a resource for preclinical drug testing! #AMPath22 attendees, visit us at booth 940 to learn more! https://t.co/GCbFmtKeB0 #cancerresearch #cancertreatments #PrecisionMedicine

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Attending #AMP2022 this week? Come visit our booth, #940, to learn more about how CKB can be used for interpreting genomic variants and finding relevant treatments and #clinicaltrials! #precisionmedicine #genomics #CancerResearch

[Stephen V Liu, MD @StephenVLiu]

Early results from phase I ARROS-1 trial: NVL-520 in #ROS1 by Dr. @alexdrilon at #ENA2022. This novel ROS1 inhibitor is designed to avoid #NTRK (and TRK-related toxicities, which often limit dose intensity). Studied in a heavily pretreated population (71% with ≥2 TKIs and chemo)

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Updates to CKB CORE and BOOST 👏! We've made some changes to improve search performance and enhance the search results for "Explore by Variant"! Check out this screenshot for--> #BRAFV600E in CKB CORE #CancerResearch #genomics #precisionmedicine

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Are you attending #AMP2022? JAX-CKB will be there! Come visit us at booth #940 and learn how CKB can be used to interpret #cancer genomic profiles and identify treatment options! #precisionmedicine #cancerresearch #clinicaltrials

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

CKB CORE users--> the next quarterly update to the gene list is now available! This quarter's theme is the tumor suppressor genes! https://t.co/xFBnGRLDpw #cancerresearch #genomics

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Check out this latest commentary on how to choose the best interpretation tools for your #oncology data! #precisionmedicine #genomics #CancerResearch https://t.co/qY7apimtkk

[Hakan Ceylan @drhakanceylan]

Check out our new publication: Remotely Guided Immunobots Engaged in Anti-Tumorigenic Phenotypes for Targeted Cancer Immunotherapy- where we convert live macrophages into robots for targeted immunoengineering.

https://t.co/4knQxWieIf

@NihalOlcay @metin_sitti @MayoClinic @MPI_IS

[Human Progress @HumanProgress]

"Scientists are developing numerous approaches to make [cancer] immunotherapy safer, including drafting different immune cells, like the awesomely-named natural killer cells.

Another option is Calibr’s off switch."
https://t.co/pK7F6GxmJW

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

A great updated summary from @theNCI highlighting the advances in #BreastCancer research! #BreastCancerAwarenessMonth #CancerResearch

[National Cancer Institute @theNCI]

Our recently updated summary of advances in #BreastCancer research highlights clinical advances that may soon translate into improved care as well as findings from recent studies. Check it out! https://t.co/WXPSd434K2 #BCSM

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Interesting study highlighting a new potential mechanism for resistance to immunotherapy -->cancer cells hiding within one another- "transient cell-in-cell structures" #immunotherapy #precisiononcology #CancerResearch https://t.co/lrq3tn5QNe

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Did you know a large portion of the evidence in CKB is #preclinical? Learn more about the types of preclinical data available in CKB in our latest blog post! #CancerResearch #genomics #PrecisionMedicine https://t.co/Y4FwGZAIKB

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Extensive review including the history of #immunotherapy, currently available treatment options, and future therapeutic targets across multiple #cancer types! @NaturePortfolio #PrecisionMedicine #immunoOncology https://t.co/HikBH10w4Q

[Andrea Malfettone @AMalfettonePhD]

Intriguing discussion of OMICS behind the #HER2low breast cancer by @prat_aleix at #ESMO22
✅Luminal A/B subtypes enriched in HER2Low vs HER2-0
✅Small difference between HER2-0 and HER2Low in ERBB2 mRNA expression
✅New diagnostic assays (mRNA?) needed
@OncoAlert
@myESMO

[Jens Rueter @RueterJens]

Looking forward to chairing this study with @MeghnaTrivedi3 and working with my @jacksonlab colleagues in @JAXClinicalEd and @JAX_CKB

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Exciting work going on for #KRAS #G12R-driven cancers! #cancerresearch #hotspotmutations

[Kevan Shokat @kevansf]

The to-do list is getting shorter. #G12R. The next #KRAS oncogene targeted by covalent chemistry. Great work @bignerdzzy @UCB_Chemistry @mo_hannes @ace_eckert @UCSF @HHMINEWS @UCSFCancer @acsJACS https://t.co/RupwbyreRw

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Great overview of recent papers detailing the current treatment landscape and emerging #biomarkers in advanced hepatocellular carcinoma. @CCR_AACR #HCC #PrecisionMedicine #oncology
https://t.co/T1MFCkImbL

[JAX Clinical Knowledgebase (JAX-CKB) @JAX_CKB]

Great presentation on category #variant relationships in @jacksonlab CKB by @mstzgon15! Visit booth 15 for more information 🧬#CGCAnnual2022